Skip to main content
SpringerLink
Log in

A Risk-Benefit Assessment of Irinotecan in Solid Tumours

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Irinotecan is a water-soluble camptothecin analogue. Its cytotoxicity effects are exerted through interaction with the topoisomerase I\3-DNA complex, eventually leading to cell death.

In preclinical studies, irinotecan has demonstrated abroad spectrum of activity in vitro and in vivo, and synergistic effects have been observed when it is administered in combination with other antineoplastic agents.

Phase I studies of irinotecan conducted in Europe, Japan and the US have provided useful information on optimal dosage and scheduling, as well as thorough evaluation of the toxicity profile of the drug. Phase II and III trials utilising either irinotecan alone or in innovative combinations with other drugs are currently in progress. Available data indicate that irinotecan alone or in combination with other cytotoxic agents has therapeutic potential in several types of malignancy, including colorectal, lung, ovarian, cervical and gastric cancers and non-Hodgkin’s lymphoma. It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer.

The principal toxicities associated with irinotecan are diarrhoea and leucopenia. Effective strategies have been developed to circumvent both the early- and delayed-onset diarrhoea induced by irinotecan, thus allowing safer delivery of this promising agent in the clinical setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wall ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966; 88: 3888–90

    CAS  Google Scholar 

  2. Gottlieb JA, Luce JK. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 1972; 56: 103–5

    PubMed  CAS  Google Scholar 

  3. Moertel CG, Schutt AJ, Reitemeier RJ, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95–101

    PubMed  CAS  Google Scholar 

  4. Yokokura T, Sawada S, Nokata K, et al. Antileukemic activity of new camptothecin derivatives [abstract]. Proceedings of the Japanese Cancer Association, 40th Annual Meeting: 1981; Sapparo, 228

    Google Scholar 

  5. Yokokura T, Furuta T, Sawada S, et al. Anti-tumor activity of newly synthesized, lactone ring closed and water soluble camptothecin derivative in mice [abstract]. Proceedings of the Japanese Cancer Association, 43rd Annual Meeting: 1984; Fukuoka, 261

    Google Scholar 

  6. Horwitz SB, Horwitz MS. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 1973; 33: 2834–6

    PubMed  CAS  Google Scholar 

  7. Sparato A, Kessel D. The effects of camptothecin on mammalian DNA. Biochem Biophys Acta 1973; 331: 194–201

    Google Scholar 

  8. Stevnsner T, Bohr VA. Studies on the role of topoisomerases in general, gene and strand specific DNA repair. Carcinogenesis 1993; 14: 1841–50

    PubMed  CAS  Google Scholar 

  9. Tsao YP, Russo A, Nyamuswa G, et al. Interaction between replication forks and topoisomerase I\3-DNA cleavable complexes: studies in a cell free SV40 DNA replication system. Cancer Res 1993; 53: 5908–14

    PubMed  CAS  Google Scholar 

  10. Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271–91

    PubMed  CAS  Google Scholar 

  11. Li LH, Fraser TJ, Olin EJ, et al. Action of camptothecin on mammalian cells in culture. Cancer Res 1972; 32: 2643–50

    PubMed  CAS  Google Scholar 

  12. D’Arpa P, Beardmore C, Liu LF. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 1990; 50: 6919–24

    PubMed  Google Scholar 

  13. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–8

    PubMed  CAS  Google Scholar 

  14. Van Der Zee AG, Dejong S, Keith WN, et al. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 1991; 51: 5915–20

    PubMed  Google Scholar 

  15. Takimoto CH, Arbuck SG. The camptothecins. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996: 463–84

    Google Scholar 

  16. Kawato Y, Aonuma M, Hirota Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51: 4187–91

    PubMed  CAS  Google Scholar 

  17. Kanzawa F, Kondoh H, Kwon SJ, et al. Role of carboxylesterase on metabolism of camptothecin analogue (CPT-11) in non-small-cell lung cancer cell line PC-7 cells [abstract]. Proc Am Assoc Cancer Res 1992; 33: 427

    Google Scholar 

  18. Kaneda N, Nagata H, Furuta T, et al. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 1990; 50: 1715–20

    PubMed  CAS  Google Scholar 

  19. Tsuji T, Kaneda N, Kado K, et al. CPT-11 converting enzyme from rat serum: purification and some properties. J Pharmacobiodyn 1991; 14: 341–9

    PubMed  CAS  Google Scholar 

  20. Satoh T, Hosokawa M, Atsumi R, et al. Metabolic activation of CPT-11, 7-ethyl-10-[4-piperidino)-1-piperidino]carbonyloxy camptothecin, a novel anti-tumor agent, by carboxylesterase. Biol Pharm Bull 1994; 17: 662–4

    PubMed  CAS  Google Scholar 

  21. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715–20

    PubMed  CAS  Google Scholar 

  22. Lavelle F, Bissery M-C, Andre S, et al. Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 1996; 23 Suppl. 3: 11–20

    PubMed  CAS  Google Scholar 

  23. Tanizawa A, Fujimori A, Fujimori Y, et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994; 86: 836–42

    PubMed  CAS  Google Scholar 

  24. Shimada Y, Rothenberg ML, Hilsenbeck SG, et al. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994; 5: 202–6

    PubMed  CAS  Google Scholar 

  25. Kunimoto T, Nitta K, Tanaka T, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987; 47: 5944–7

    PubMed  CAS  Google Scholar 

  26. Matsuzaki T, Yokokura T, Mutai M, et al. Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 1988; 21: 308–12

    PubMed  CAS  Google Scholar 

  27. Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192–8

    PubMed  CAS  Google Scholar 

  28. Tsuruo T, Matsuzaki T, Matsushita M, et al. Antitumor effects of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in. vitro and in vivo. Cancer Chemother Pharmacol 1988; 21: 71–4

    PubMed  CAS  Google Scholar 

  29. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in. vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 53: 2823–9

    PubMed  CAS  Google Scholar 

  30. Guichard S, Caliaro MJ, Houin G, et al. Sequential exposure to CPT-1 and 5FU is synergistic in human colon carcinoma HT-29 cell line [abstract]. Proc Am Assoc Clin Res 1996; 37: 292

    Google Scholar 

  31. Funakoshi S, Aiba K, Shibata H, et al. Enhanced antitumor activity of SN-38, an active metabolite of CPT-11, and 5-fluorouracil combination for human colorectal cancer cell lines [abstract]. Proc Am Soc Clin Oncol 1993; 12: 193

    Google Scholar 

  32. Guichard S, Hennebelle I, Cussac D, et al. In vivo evaluation of the irinotecan (CPT-11)/5-fluorouracil (5FU) combination [abstract]. Proc Am Assoc Clin Res 1997; 38: 76

    Google Scholar 

  33. Kudoh S, Takada M, Masuda N, et al. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 1993; 84: 203–7

    PubMed  CAS  Google Scholar 

  34. Furuta T, Yokokura T. Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L1210 leukemia. Jpn J Cancer Chemother 1991; 18: 393–402

    CAS  Google Scholar 

  35. Kaufmann S. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemic cell line. Cancer Res 1991; 51: 1129–36

    PubMed  CAS  Google Scholar 

  36. Bertrand R, O’Connor PM, Kerrigan D, et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer 1992; 28A: 743–8

    PubMed  CAS  Google Scholar 

  37. Kim R, Hirabayashi N, Nishiyama M, et al. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760–6

    PubMed  CAS  Google Scholar 

  38. Rowinsky EK, Grochow LB, Ettinger DS, et al. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycampto thecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994; 54: 427–36

    PubMed  CAS  Google Scholar 

  39. Abigerges D, Chabot GG, Armand J-P, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210–21

    PubMed  CAS  Google Scholar 

  40. Rothenberg ML, Kuhn JG, Burris III HA, et al. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993; 11: 2194–204

    PubMed  CAS  Google Scholar 

  41. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164–8

    PubMed  CAS  Google Scholar 

  42. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128–35

    PubMed  CAS  Google Scholar 

  43. Taguchi T, Wakui A, Hasegawa K, et al. Phase I clinical study of CPT-11. Jpn J Cancer Chemother 1990; 17: 115–20

    CAS  Google Scholar 

  44. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515–21

    PubMed  CAS  Google Scholar 

  45. Nagata H. Flow cytometric analysis of the effect of an antitumor alkaloid, camptothecin, on cell cycle progression of KB cell. J Aichi Med Univ Assoc 1987; 15: 683–99

    CAS  Google Scholar 

  46. Rothenberg ML, Rinaldi DA, Smith LS, et al. Every other week irinotecan (CPT-11): results of a phase I and pharmacokinetic (PK) study [abstract]. Proc Am Soc Clin Oncol 1996; 15:489

    Google Scholar 

  47. Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–13

    PubMed  CAS  Google Scholar 

  48. Pitot HC, Wender DB, O’Connell MT, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910–9

    PubMed  CAS  Google Scholar 

  49. Van Cutsem E, Cunningham D, Ten Bokkel Huinink W, et al. CPT-11 in 5-FU-resistant colorectal cancer: patient benefit [abstract]. European Society of Medical Oncology Symposium: 1996 Nov 2–5; Vienna

    Google Scholar 

  50. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251–60

    PubMed  CAS  Google Scholar 

  51. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 709–15

    PubMed  CAS  Google Scholar 

  52. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials [abstract]. Proc Am Soc Clin Oncol 1997; 16: 228a

    Google Scholar 

  53. Nakai H, Fukuoka M, Furese K, et al. An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 1991; 18: 607–12

    CAS  Google Scholar 

  54. Negoro S, Fukuoka M, Kusunoki Y, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 18: 1013–9

    CAS  Google Scholar 

  55. Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 461a

    Google Scholar 

  56. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992; 10: 16–20

    PubMed  CAS  Google Scholar 

  57. Douillard JY, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1995; 14: 365

    Google Scholar 

  58. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992; 10: 1225–9

    PubMed  CAS  Google Scholar 

  59. Le Chevalier T, Ibrahim N, Chomy P, et al. A phase II study of irinotecan (CPT-11) in patients (pts) with small cell lung cancer (SCLC) progressing after initial response to first-line chemotherapy (CT) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 450a

    Google Scholar 

  60. Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Jpn J Cancer Chemother 1991; 18: 1681–9

    CAS  Google Scholar 

  61. Potkul RK, Price FV, Bailey H, et al. Irinotecan (CPT-11) in advanced squamous cell carcinoma of the cervix (phase II) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 279

    Google Scholar 

  62. Verschraegen CF, Levy T, Kudelka AP, et al. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 1997; 15: 625–31

    PubMed  CAS  Google Scholar 

  63. Chevallier B, Lhomme C, Dieras V, et al. Phase II trial of CPT-11 in advanced cervical carcinoma [abstract]. EORTC Early Drug Development Meeting: 1995 Jun 21–24; Corfu, 92

    Google Scholar 

  64. Taguchi T, Tominaga T, Ogawa M, et al. A late phase II study of CPT-11 (irinotecan) in advanced breast cancer. CPT-11 Study Group on Breast Cancer. Jpn J Cancer Chemother 1994; 21: 1017–24

    CAS  Google Scholar 

  65. Bonneterre J, Pion JM, Adenis A, et al. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients [abstract]. Proc Am Soc Clin Oncol 1993; 12: 94

    Google Scholar 

  66. Sakata Y, Shimada Y, Yoshino M, et al. A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer. Jpn J Cancer Chemother 1994; 21: 1039–46

    CAS  Google Scholar 

  67. Wagener DJ, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials groups study. Ann Oncol 1995; 6: 129–32

    PubMed  CAS  Google Scholar 

  68. Futatsuki K, Wakui A, Nakao I, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. Jpn J Cancer Chemother 1994; 21: 1033–8

    CAS  Google Scholar 

  69. Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 1990; 8: 1907–12

    PubMed  CAS  Google Scholar 

  70. Shimada Y, Sasaki Y, Sugano K, et al. Combination phase I study of CPT-11 (irinotecan) combined with continuous infusion of 5-fluorouracil (5-FU) in metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: 196

    Google Scholar 

  71. Benhammouda A, Bastian G, Rixe O, et al. A phase I and pharmacokinetic (PK) study of CPT-11 (C) and 5-FU (F) combination [abstract]. Proc Am Soc Clin Oncol 1997; 16: 202a

    Google Scholar 

  72. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: 2959–67

    PubMed  CAS  Google Scholar 

  73. Parnes HL, Tait N, Conley B, et al. A phase I study of CPT-11, weekly bolus 5-FU and leucovorin in patients with metastatic cancer. Oncol Rep 1995; 2: 1131–4

    PubMed  CAS  Google Scholar 

  74. Rougier Ph, Ychou M, Seitz JF, et al. Phase I/II study of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5FU failure [abstract]. The European Cancer Conference 9: 1997 Sep 14–18; Hamburg, S169

    Google Scholar 

  75. Ducreux M, Rougier PH, Ychou M, et al. PhaseI/II study of escalating doses of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks in the treatment of colorectal cancer (CRC) after 5-FU failure [abstract]. Proc Am Soc Clin Oncol 1997; 16: 234a

    Google Scholar 

  76. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994; 86: 1096–8

    PubMed  CAS  Google Scholar 

  77. Karato A, Sasaki Y, Shinkai T, et al. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11: 2030–5

    PubMed  CAS  Google Scholar 

  78. Saltz L, Kanowitz J, Kelsen D, et al. Phase I study of weekly cisplatin (CDDP) plus irinotecan (CPT-11) in patients (PTS) with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 1996; 15: 484

    Google Scholar 

  79. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994: 12: 1833–41

    PubMed  CAS  Google Scholar 

  80. Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 1992; 10: 1775–80

    PubMed  CAS  Google Scholar 

  81. Masuda N, Fukuoka M, Kudoh S, et al. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 1993; 68: 777–82

    PubMed  CAS  Google Scholar 

  82. Ueoka H, Tabata M, Shibayama T, et al. A phase I study of irinotecan (CPT-11) and cisplatin (CDDP) in advanced lung cancer (ED-SCLC and IIIB/IV-NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 385

    Google Scholar 

  83. Kobayashi K, Soma T, Shinbara A, et al. Phase I study of irinotecan (CPT-11) and cisplatin (CDDP) by divided administration in patients with non-small-cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15: 388

    Google Scholar 

  84. Masuda N, Fukuoka M, Kudoh S, et al. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90–6

    PubMed  CAS  Google Scholar 

  85. Mori K, Ohnishi T, Yokoyama K, et al. A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 39: 327–32

    PubMed  CAS  Google Scholar 

  86. Shinkai T, Arioka H, Kunikane H, et al. Phase I clinical trial of irinotecan (CPT-ll), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54: 2636–42

    PubMed  CAS  Google Scholar 

  87. Shirao K, Shimada Y, Kondo H, et al. Phase I–II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15: 921–7

    PubMed  CAS  Google Scholar 

  88. Rothenberg ML, Pazdur R, Rowinsky EK, et al. A phase II multicenter trial of alternating cycles of irinotecan (CPT-11) and 5-FU/LV in patients with previously untreated metastatic colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 266a

    Google Scholar 

  89. Barone C, Pozzo C, Starkhammar H, et al. CPT-11 alternating with 5-fluorouracil (5-FU)/folinic acid (FA): a multicentre phase II study in first-line chemotherapy (CT) of metastatic colorectal cancer (CRC) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 270a

    Google Scholar 

  90. Oshita F, Noda K, Nishiwaki Y, et al. Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1997; 15: 304–9

    PubMed  CAS  Google Scholar 

  91. DeVore R, Crawford J, Dimery I, et al. Phase II trial of irinotecan (CPT-11) plus cisplatin (CDDP) in advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 1997; 16: 466a

    Google Scholar 

  92. Mori K, Hirose T, Tominaga K. Phase II study irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 476a

    Google Scholar 

  93. Saka H, Shimokata K, Yoshida K, et al. Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG9504) [abstract]. Proc Am Soc Clin Oncol 1997; 16: 447a

    Google Scholar 

  94. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998; 16: 1068–74

    PubMed  CAS  Google Scholar 

  95. Sugiyama T, Nishida T, Ushijima K, et al. Irinotecan hydrochloride (CPT-11) combined with cisplatin (CDDP) in patients with relapsed or metastatic ovarian cancer [abstract]. Proc Am Soc Clin Oncol 1996; 15: 291

    Google Scholar 

  96. Shimizu Y, Umezawa S, Hasumi K. Combination of CPT-11 (CPT) with mitomycin-C (MMC) is active for clear cell adenocarcinoma of the ovary (OCA) which is intrinsically CDDP-resistant [abstract]. Proc Am Soc Clin Oncol 1996; 15: 282

    Google Scholar 

  97. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of CDDP and CPT-11 in metastatic gastric cancer: CPT-11 study group for gastric cancer [abstract]. Proc Am Soc Clin Oncol 1997; 16: 264a

    Google Scholar 

  98. Poon MA, O’Connell MJ, Wieand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therpeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967–72

    PubMed  CAS  Google Scholar 

  99. Gandia D, Abigerges D, Armand JP, et al. CPT-11-induced cholinergic effects in cancer patients. J Clin Oncol 1993; 11: 196–7

    PubMed  CAS  Google Scholar 

  100. Bleiberg H, Cvitkovic E. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer 1996; 32A Suppl. 3: S18–23

    PubMed  CAS  Google Scholar 

  101. O’Reilly S, Rowinsky R. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol 1996; 24: 47–70

    PubMed  Google Scholar 

  102. Chen G, Portman R, Wickel A. Pharmacology of 1,1-dimethyl-4-phenyl-piperazinium iodide, a ganglion-stimulating agent. J Pharmacol Exp Ther 1951; 103: 330–6

    PubMed  CAS  Google Scholar 

  103. Abigerges D, Armand JP, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446–9

    PubMed  CAS  Google Scholar 

  104. Goncalves E, da Costa L, Abigerges D, et al. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 1996; 13: 2144–6

    Google Scholar 

  105. Ychou M, Rougier Ph, Oberling F, et al. Aphase II randomized study of CPT-11 (irinotecan) in colorectal cancer (CRC) refractory to 5-FU, with preventive treatment of delayed diarrhea using acetorphan [abstract]. Proc Am Soc Clin Oncol 1996; 15: 212

    Google Scholar 

  106. Hagipantelli R, Saliba F, Misset JL, et al. Pathophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea: a prospective assessment [abstract]. Proc Am Soc Clin Oncol 1995; 14: 464

    Google Scholar 

  107. Ikuno N, Soda H, Watanabe M, et al. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J Natl Cancer Inst 1995; 87: 1876–83

    PubMed  CAS  Google Scholar 

  108. de Forni M, Bugat R, Chabot GG, et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 1994; 54: 4347–54

    PubMed  Google Scholar 

  109. Catimel G, Chabot GG, Guastalla JP, et al. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 1995; 6: 133–40

    PubMed  CAS  Google Scholar 

  110. Sasaki Y, Hakusui H, Mizuno S, et al. A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 1995; 86: 101–10

    PubMed  CAS  Google Scholar 

  111. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723–5

    PubMed  CAS  Google Scholar 

  112. Atsumi R, Suzuki W, Hakusui H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 1991; 21: 1159–69

    PubMed  CAS  Google Scholar 

  113. Rivory LP, Robert J. Identification and kinetics of a β-glucuronide of SN-38 in human plasma after administration of the camptothecin derivative irinotecan (CPT-11). Cancer Chemother Pharmacol 1995; 36: 176–9

    PubMed  CAS  Google Scholar 

  114. Lokiec F, Canal P, Gay C, et al. Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 1995; 36: 79–82

    PubMed  CAS  Google Scholar 

  115. Araki E, Ishikawa M, Iigo M, et al. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84: 697–702

    PubMed  CAS  Google Scholar 

  116. Boddy AV, Ratain MJ. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res 1997; 3: 1025–30

    PubMed  CAS  Google Scholar 

  117. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837–55

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Drug Development, Cancer Therapy and Research Center, 8122 Datapoint Drive, Suite 700, San Antonio, Texas, TX 78229-3264, USA

    Lillian L. Siu &  Eric K. Rowinsky

Authors
  1. Lillian L. Siu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric K. Rowinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siu, L.L., Rowinsky, E.K. A Risk-Benefit Assessment of Irinotecan in Solid Tumours. Drug-Safety 18, 395–417 (1998). https://doi.org/10.2165/00002018-199818060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199818060-00002

Keywords

Search

Navigation